CClinicalTrials.gg
Active, not recruitingNCT05716243Updated Mar 19, 2025

Nociception Level Index as a Verbal Tool of Pain in Children

An interventional study of The nociception level index monitorization and The nociception level index measurement;postoperative in Pediatric Patients, Orthopedic Surgery and Extremity Fractures Lower, sponsored by Haseki Training and Research Hospital. Active, not recruiting at 1 site in Turkey. Open to participants aged 1 Year to 6 Years. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Haseki Training and Research Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 4 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
1 Year to 6 Years
Sex
All
01

Study summary

60 children under 6 years old, scheduled for orthopedic surgery for limb fracture or neuromuscular and bone deformities will be randomized by closed envelope method into two groups (n=30) either receiving standard pain management protocol or intraoperative NOL guided analgesia. Our study aims to evaluate the nociception monitor's effectiveness in providing adequate postoperative analgesia in pediatric patients. Besides, the difference between the amount of analgesic medication will be recorded.

Data to be recorded are total intraoperative morphine and postoperative rescue analgesic consumption, NOL values, and FLACC scores.

Read the detailed description

The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives). Moreover, its design as a finger probe connected to a non-invasive continuous nociception monitor makes it more suitable, especially for pediatric patients. Although this monitor has been validated for discrimination of a noxious stimulus with high accuracy, its effects on perioperative pain management have recently started to be shown in clinical practice. More importantly, no study has yet been conducted on the use of NOL monitoring in pain management in pediatric patients.

The study is designed as a single-blind, prospective study after approval of our Institutional ethics committee (dossier no:211-2022) and planned to allocate 60 patients (2 groups; 1:1 allocation; n=30) after obtaining written informed parental consent. Children aged under 6 who are scheduled for orthopedic surgery for limb fracture or neuromuscular and bone deformities are eligible for this study. Exclusion criteria are refusal to participate in the study; history of premature birth; known metabolic syndrome; allergies to drugs used within the study protocol; decreased liver or renal function; diagnosed mental retardation.

Patient randomization Randomization is designed with concealed opaque envelope in a 1:1 ratio into 2 groups (n= 30): the control group (Group A) and the study group (Group B). Before the start of the study, an independent anesthetist will prepare 60 envelopes each containing the name of one group. When the inclusion/exclusion criteria are met, on the day of the surgery the anesthetist will choose one envelope in the operating room to apply the designed protocol for each group. Data obtained at the clinical follow-up will be gathered by an independent anesthetist who is blinded to the groups and protocol used in the operating room.

Anesthesia, intervention, and post-interventional follow-up After standard monitorization, general anesthesia induction will start with sevoflurane 4-6% administered via a face mask. Subsequently, after intravenous (IV) cannulation 2 mcg/kg fentanyl; 0,05 mg/kg midazolam; 1-2,5 mg/kg propofol; 0,6 mg/kg rocuronium will be administered and orotracheal intubation will be performed. Once the randomization is concluded to decide the group of the patient, Group A will receive 15 mg/kg (IV) paracetamol and 0,05 mg/kg morphine (IV). For once, NOL monitorization will be applied 30 minutes before waking up the patient to assess standard pain management and if the NOL value is higher than 25; 0,025 mg/kg morphine (IV) bolus doses (the maximum total intraoperative dose is concluded to be 0,5 mg/kg (IV)) will be added to ensure adequate analgesia for all patients within the study. On the contrary, patients within Group B will receive NOL monitorization from the beginning, all along the surgery. As pain management protocol, other than standard 15 mg/kg (IV) paracetamol, 0,025 mg/kg morphine (IV) bolus doses will be applied if only intraoperative NOL values are over 25 (concluded to be valuable only if it remains over 25 for at least one minute). Postoperative pain was assessed by FLACC (Face, Legs, Activity, Cry, Consolability) behavioral pain assessment score at the postoperative care unit, 6th 12th, and 24th hour postoperatively. The same anesthetist who is blind to study groups will make all assessments to precise standardization. All children will be prescribed paracetamol 15 mg/kg (IV) four times per day. If the pain score was equal to or more than 4, tramadol 1 mg/kg will be administered intravenously as a rescue analgesic. The amount of total intraoperative morphine and postoperative rescue analgesic consumption along with NOL values and FLACC scores will be recorded.

02

Conditions studied

  • Pediatric Patients
  • Orthopedic Surgery
  • Extremity Fractures Lower
  • Extremity Fractures Upper
  • Deformity; Congenital

Keywords

  • postoperative pain
  • nociception level index
  • behavioral pain scores
  • general anesthesia
  • pain monitorization
03

In context

Congenital Abnormalities

980 studies on the registry are indexed under Congenital Abnormalities; 177 are open to participants now.

This study's planned enrollment of 60 is above the median of 49 across 491 interventional studies indexed under Congenital Abnormalities.

Browse Congenital Abnormalities studies →

Lead sponsor

Haseki Training and Research Hospital is the lead sponsor of 75 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • American Society of Anaesthesiologists (ASA) Physical Status classification I to II
  • Patients whose parents will give informed consent for the study

Exclusion criteria

Exclusion Criteria:

  • Refusal to take part in the study
  • History of allergies to drugs used in the study protocol
  • History of premature birth
  • Diagnosed metabolic syndrome
  • Known hepatic insufficiency or decreased function
  • Known renal insufficiency or decreased function
  • Diagnosed with mental retardation
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Group A

    Group A will receive a standard intraoperative analgesia protocol

    Device: The nociception level index measurement;postoperative

  • Experimental
    Group B

    Group B will receive a NOL-guided analgesia protocol

    Device: The nociception level index monitorization

Interventions

  • DeviceThe nociception level index monitorization

    The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives).

  • DeviceThe nociception level index measurement;postoperative

    The nociception level index (NOL) will be used postoperatively

06

What researchers measure

Primary outcomes

  1. Pain Scores

    Face, Legs, Activity, Cry, Consolability (FLACC) behavioral pain assessment score : range 0-10; 0 = Relaxed and comfortable;1-3 = Mild discomfort; 4-6 = Moderate. pain. 7-10 = Severe discomfort/pain.

    Time frame: postoperative 24 hour

Secondary outcomes

  1. The total amount of analgesic drug

    morphine(mg) used intraoperatively and tramadol(mg) at postoperative follow-up

    Time frame: Intraoperative and postoperative 24 hour

07

Study locations

1 site
  • Haseki Training and Research Hospital
    Istanbul, Sultangazi 34000, Turkey
08

References and documents

Publications

  • Gomez-Rios MA, Abad-Gurumeta A, Calvo-Vecino JM. Assessing nociception: steps towards intraoperative "full monitoring". Minerva Anestesiol. 2018 Oct;84(10):1123-1125. doi: 10.23736/S0375-9393.18.13191-9. No abstract available. PubMed 30274508 ↗
  • Ghiyasinasab M, Morisson L, Laferriere-Langlois P, Geraldo-Demers MA, Gelinas C, Nadeau-Vallee M, Verdonck O, Lahrichi N, Richebe P. Identification of the intraoperative antinociceptive effect of intravenous fentanyl using the Nociception Level (NOL) index versus clinical parameters in patients undergoing gynecological laparoscopic surgery: A secondary analysis of the NOLGYN study. Anaesth Crit Care Pain Med. 2022 Aug;41(4):101102. doi: 10.1016/j.accpm.2022.101102. Epub 2022 May 25. PubMed 35643392 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05716243
Lead sponsor
Haseki Training and Research Hospital
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Jan 10, 2023
Primary completion
May 30, 2025 (estimated)
Completion
Jun 15, 2025 (estimated)
Last update
Mar 19, 2025

Study contacts

Berna Caliskan, MD
principal investigator · Haseki Training and Research Hospital Anesthesiology and Reanimation Department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion